|
Wednesday, September 4, 2024, Houston, Texas, 7:30 PM – 8:30 PM Central Time (8:30 PM – 9:30 PM Eastern Time)
Data and Perspectives: Clinical Investigators Discuss the Current and Future Management of Diffuse Large B-Cell LymphomaPart 2 of a 2-Part CME Satellite Symposium Series During the Society of Hematologic Oncology 2024 Annual Meeting
Date and Time
Wednesday, September 4, 2024 7:30 PM – 8:30 PM Central Time Educational Dinner Meeting Location George R Brown Convention Center 1001 Avenida de las Americas Houston, Texas 77010 Phone: (713) 853-8000 Meeting Room Level 3 in Grand Ballroom C (Theater 2) This event will also be webcast live. Please see Registration tab for details. Faculty
Grzegorz S Nowakowski, MD Professor of Medicine and Oncology Chair, Lymphoid Malignancy Group Enterprise Deputy Director, Clinical Research Mayo Clinic Comprehensive Cancer Center Vice-Chair, Division of Hematology Mayo Clinic Rochester, Minnesota Laurie H Sehn, MD, MPH Chair, Lymphoma Tumour Group BC Cancer Centre for Lymphoid Cancer Clinical Professor of Medicine Division of Medical Oncology University of British Columbia Podcast Editor, Blood Vancouver, British Columbia, Canada
Moderator
Christopher R Flowers, MD, MS Chair ad Interim, Division of Cancer Medicine Professor, Department of Lymphoma/Myeloma The University of Texas MD Anderson Cancer Center Houston, Texas This CE activity is supported through educational grants from ADC Therapeutics, Genentech, a member of the Roche Group, and Genmab US Inc and AbbVie Inc.
Date and Time
Wednesday, September 4, 2024 7:30 PM – 8:30 PM Central Time Educational Dinner Meeting Topics to be announced. Target Audience
CE Credit Support Statement FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Dr Nowakowski — Consulting Agreements: AbbVie Inc, ADC Therapeutics, Bantam Pharmaceutical, Blueprint Medicines, Bristol Myers Squibb, Celgene Corporation, Curis Inc, Daiichi Sankyo Inc, Debiopharm, F Hoffmann-La Roche Ltd, Fate Therapeutics, Genentech, a member of the Roche Group, Incyte Corporation, Karyopharm Therapeutics, Kite, A Gilead Company, Kymera Therapeutics, MEI Pharma Inc, MorphoSys, Ryvu Therapeutics, Seagen Inc, Selvita, TG Therapeutics Inc, Zai Lab. Additional faculty to be announced. MODERATOR — Dr Flowers — Advisory Committees and Consulting Agreements: AbbVie Inc, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Celgene Corporation, Denovo Biopharma, Foresight Diagnostics, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Janssen Biotech Inc, Karyopharm Therapeutics, N-Power Medicine Inc, Pharmacyclics LLC, an AbbVie Company, Seagen Inc, Spectrum Pharmaceuticals Inc; Contracted Research: 4D Pharma PLC, AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Allogene Therapeutics, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Cellectis, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Guardant Health, Iovance Biotherapeutics, Janssen Biotech Inc, Kite, A Gilead Company, MorphoSys, Nektar Therapeutics, Novartis, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi, Takeda Pharmaceuticals USA Inc, TG Therapeutics Inc, Xencor, ZIOPHARM Oncology Inc; Stock Options – Private Company: Foresight Diagnostics, N-Power Medicine Inc; Nonrelevant Financial Relationships: Burroughs Wellcome Fund, Cancer Prevention and Research Institute of Texas (CPRIT Scholar in Cancer Research), Eastern Cooperative Oncology Group, National Cancer Institute, V Foundation. Planning Committee and Content/Peer Reviewers — The planners and content/peer reviewers from Medical Learning Institute, Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.This Independent Satellite Symposium is not an official program of the Society of Hematologic Oncology 2024 Annual Meeting. It is not sponsored or endorsed by the Society of Hematologic Oncology. George R Brown Convention Center
This activity is intended for hematologists, hematology-oncology fellows, medical oncologists and other healthcare providers involved in the treatment of diffuse large B-cell lymphoma (DLBCL).
There is no fee to participate in this hybrid event. In order to attend the in-person symposium in Houston, you must also be registered to attend the SOHO 2024 Annual Meeting. Preregistration (below) is required as seating is limited for this program. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
LIVE WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 15 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153. |